The DOI matches its Crossref record; 147 of the 147 references it cites were found in a registry or an index.
GABAergic Function in Alzheimer's Disease: Evidence for Dysfunction and Potential as a Therapeutic Target for the Treatment of Behavioural and Psychological Symptoms of Dementia
Open accessAbstract
Alzheimer's disease (AD) is characterized by disruptions in multiple major neurotransmitters. While many studies have attempted to establish whether GABA is disrupted in AD patients, findings have varied. We review evidence for disruptions in GABA among patients with AD and suggest that the variable findings reflect subtypes of the disease that are possibly manifested clinically by differing behavioural symptoms. GABA, the major inhibitory neurotransmitter, has long been a target for anxiolytics, hypnotic sedatives, and anticonvulsants. We review the clinical use of GABAergic agents in treating persons with AD symptoms. While newer generation GABAergic medications are now available, they have yet to be evaluated among patients with AD.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Loss of GABA, the primary inhibitory neurotransmitter in the brain, is a key component of AD.”
From Apolipoprotein E4, inhibitory network dysfunction, and Alzheimer’s disease (2019) · cites this paper as [85]
In the citing paper
“However, across several clinical trials, these agents have produced behavioral, but not cognitive, improvements [85].”
From Apolipoprotein E4, inhibitory network dysfunction, and Alzheimer’s disease (2019) · cites this paper as [85]
Citations
Cites
Psychopharmacology: The third generation of progress
O’Connell, R. A. (1988) · Comprehensive Psychiatry · doi:10.1016/0010-440x(88)90057-0 · Cited by 3,020
Perry, E., Tomlinson, B. E., Blessed, G., Bergmann, K., Gibson, P., & Perry, R. H. (1978) · British medical journal · doi:10.1136/bmj.2.6150.1457 · Cited by 2,043
Psychopharmacology: The Third Generation of Progress.
(1988) · Annals of Internal Medicine · doi:10.7326/0003-4819-108-3-509_2 · Cited by 2,021
The Biochemical Basis of Neuropharmacology.
(1974) · Annals of Internal Medicine · doi:10.7326/0003-4819-81-4-575_2 · Cited by 1,882
Alzheimer disease: Evidence for selective loss of cholinergic neurons in the nucleus basalis
Whitehouse, P. J., Price, D. L., Clark, A. W., Coyle, J. T., & DeLong, M. R. (1981) · Annals of Neurology · doi:10.1002/ana.410100203 · Cited by 1,736
Benzodiazepine actions mediated by specific γ-aminobutyric acidA receptor subtypes
Rudolph, U., Crestani, F., Benke, D., Brünig, I., Benson, J. A., Fritschy, J.-M., Martin, J. R., Bluethmann, H., & Möhler, H. (1999) · Nature · doi:10.1038/44579 · Cited by 1,172
Diagnosis and Treatment of Alzheimer Disease and Related Disorders
Small, G. W. (1997) · JAMA · doi:10.1001/jama.1997.03550160083043 · Cited by 992
Molecular and neuronal substrate for the selective attenuation of anxiety
Löw, K., Crestani, F., Keist, R., Benke, D., Brünig, I., Benson, J. A., Fritschy, J.-M., Rülicke, T., Bluethmann, H., Möhler, H., et al. (2000) · Science · doi:10.1126/science.290.5489.131 · Cited by 946
McKernan, R. M., Rosahl, T. W., Reynolds, D. S., Sur, C., Wafford, K. A., Atack, J. R., Farrar, S., Myers, J., Cook, G., Ferris, P., et al. (2000) · Nature Neuroscience · doi:10.1038/75761 · Cited by 944
Neurotransmitter-related enzymes in senile dementia of the alzheimer type
Davies, P. (1979) · Brain Research · doi:10.1016/0006-8993(79)90336-6 · Cited by 634
Research works printed but not linked: 22
- Canadian Study of Health and Aging Working Group, 1994, Can Med Assoc J, 150, 899
- Malick JB, 1970, Arch Int Pharmacodyn Ther, 184, 252
- Delgado JMR, 1973, Antiaggressive effects of chlordiazepoxide
- Sedvall G, 1987, J Neural Transm Suppl, 24, 43
- Sherif F, 1995, Neurodegeneration, 4, 114
- Fukuchi K, 1997, J Nucl Med, 38, 467
- Wyper D, 1998, Inter J Geriatr Psychopharmacol, 1, 126
- Oishi M, 1996, Ann Clin Lab Sci, 26, 340
- Kuroda H., 1983, Acta Med Okayama, 37, 167
- Bareggi SR, 1982, Age or disease-related modifications? Arch Neurol, 39, 709
- Freinhar JP, 1986, J Clin Psychiatry, 47, 525
- Fritz J, 1990, Am J Psychiatry, 147
- Sanders JF, 1965, Geriatrics, 20, 739
- Beber CR, 1965, Dis Nerv Syst, 26, 591
- Chesrow EJ, 1965, Clin Med, 71, 1001
- Herz LR, 1992, Hosp Community Psychiatry, 43, 720
- Marin DB, 1989, Am J Psychiatry, 146
- Lemke MR, 1995, J Clin Psychiatry, 56, 354
- Gleason RP, 1990, J Clin Psychiatry, 51, 115
- Gupta S, 1998, Int J Geriatr Psychopharmacol, 1, 244
- Fahs H, 1999, Encephale, 25, 169
- Horne M, 1995, J Clin Psychiatry, 56, 430
Cited by
Sorted by citations
The Gut Microbiota and Alzheimer’s Disease
Jiang, C., Li, G., Huang, P., Liu, Z., & Zhao, B. (2017) · Journal of Alzheimer's Disease · doi:10.3233/jad-161141 · Cited by 852
“Postmortem studies of the cortical areas of AD patients have shown reduced frontal, temporal, and parietal GABA concentrations (for review, see [58]).”
Rajmohan, R., & Reddy, P. H. (2016) · Journal of Alzheimer s Disease · doi:10.3233/jad-160612 · Cited by 730
“Because ofthis,stimulatingGABAergictransmissionhas beenattemptedtotreatbehavioralandpsychologi-caldysfunctionsinAD[52,61],buttheseeffortsare limitedduetoissuesoftoleranceafterlong-termuse andsideeffects[52,62].”
Alzheimer’s disease and gut microbiota
Hu, X., Wang, T., & Jin, F. (2016) · Science China Life Sciences · doi:10.1007/s11427-016-5083-9 · Cited by 371
The impact of the microbiota-gut-brain axis on Alzheimer’s disease pathophysiology
Doifode, T., Giridharan, V. V., Generoso, J. S., Bhatti, G., Collodel, A., Schulz, P. E., Forlenza, O. V., & Barichello, T. (2021) · Pharmacological Research · doi:10.1016/j.phrs.2020.105314 · Cited by 347
Loss of functional GABA A receptors in the Alzheimer diseased brain
Limón, A., Reyes‐Ruiz, J. M., & Miledi, R. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1204606109 · Cited by 275
“Early studies of the temporal cortex, an area greatly affected by the neuropathic hallmarks of AD, showed only slight decreases (13–17%) of benzodiazepine binding (2, 5), suggesting a modest decrease of GABAARs in AD.”
Background
Metadata
- Authors
- Lanctôt, K. L., Herrmann, N., Mazzotta, P., Khan, L. R., & Ingber, N.
- Affiliations
- Sunnybrook Health Science Centre (CA)
- Corresponding author
- Lanctôt, Krista L
- Venue
- The Canadian Journal of Psychiatry
- Publisher
- SAGE Publications
- Published
- 2004-07
- Volume
- 49
- Issue
- 7
- Pages
- 439-453
- ISSN
- 0706-7437 (ISSN-L)
- 1497-0015
- OpenAlex
- W2184602814
- Cited by
- 191
- References
- 146
- Citations by year
- 2025: 7 · 2024: 6 · 2023: 6 · 2022: 11 · 2021: 14 · 2020: 12 · 2019: 13 · 2018: 19 · 2017: 15 · 2016: 11 · 2015: 9 · 2014: 8 · 2013: 9 · 2012: 6
- FWCI
- 3.09
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- The Canadian Journal of Psychiatry (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Alzheimer's Society
- Topics
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neuroscience and Neuropharmacology Research
- Keywords
- Alzheimer's disease, GABA, GABAergic dysfunction, behavioral and psychological symptoms of dementia, inhibitory neurotransmitter, GABAergic drugs, anxiolytics, antiepileptic drugs, disease subtypes
- MeSH terms
- Aged, Alzheimer Disease, Benzodiazepines, Binding Sites, Brain, Frontal Lobe, gamma-Aminobutyric Acid, Humans, Limbic System, Parietal Lobe, Temporal Lobe, Tomography, Emission-Computed, Tomography, Emission-Computed, Single-Photon, Receptors, GABA, GABA Agonists
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
